NY-LIFEZONE-METALS
26.2.2024 12:01:30 CET | Business Wire | Press release
Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, is pleased to provide an update on progress of the Definitive Feasibility Study underway at its Kabanga Nickel Project, located in north-west Tanzania, and at Kahama, where Kabanga’s Hydromet refinery will be located. Kabanga is believed to be one of the world’s largest and highest grade undeveloped nickel sulfide deposits. The Kahama Hydromet Refinery will allow for in-country beneficiation of nickel, copper and cobalt with low carbon dioxide and zero sulfur dioxide emissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226757968/en/
Figure 1: Early Years Blend Composite locked-cycle flotation test work showing concentrate nickel grade versus. nickel recovery. Source: Bureau Veritas Minerals Pty Ltd, Project No. 4668, Locked Cycle Test 2 (LCT2 EYBC). The Locked Cycle Test final product result is based on the average performance of cycles 4 to 6 of the test, at steady state. The Locked Cycle Test curve is derived from the rougher concentrate only and the high-grade concentrate streams of the same test for the same cycles 4 to 6. The curve also reflects and is validated by the open-cycle testing results on the same Early Years Blend Composite sample.
Lifezone Metals has determined that a two-phase development plan for its Kabanga Nickel Project will form the base case of the Definitive Feasibility Study. Design work and mine planning to-date supports an expected 3.4 million tonnes per year operation in the aggregate, comprised of a 1.7 million tonne per year Phase 1 and an additional 1.7 million tonne per year Phase 2 expansion.
The Company continues to collaborate closely with its project partner on this two-phased development plan, as well as numerous other Definitive Feasibility Study work streams. Lifezone Metals is working to evolve and integrate sustainability across Project planning, implementation and in-country operational readiness.
The Kabanga Nickel Project Definitive Feasibility Study, which evaluates the technical specifications and economic business case of the Kabanga Underground Nickel-Copper-Cobalt Mine, Kabanga Concentrator and Kahama Hydromet Refinery, is a work-in-progress and mine planning continues, including the application of modifying factors to establish the economic viability of Mineral Reserves, with various major capital items tendered. The study remains on track for completion by the end of Q3 2024.
Mr. Showalter stated: “We have made solid progress advancing the Kabanga Definitive Feasibility Study, which is progressing both on-time and on-budget, with activities occurring across various countries (Tanzania, South Africa and Australia). Ongoing refinement of the development plan and metallurgical testing is aimed at maximizing the net present value of the Project while optimizing capital outlays. We are grateful for the strong support and collaboration from project partner, our local communities and the Tanzanian government, which continues to deliver on key milestones critical to keeping the Project on track.”
Separate programs of extensive metallurgical testing continue in support of process designs for 1) the Kabanga Concentrator and 2) the Kahama Hydromet Refinery.
Kabanga Concentrator Test Work Achieves High Nickel Recovery of 88.2% to a Clean 18.8% Nickel Concentrate
Kabanga Concentrator test work conducted on a range of variability composite samples sourced from the 2023 drilling program, representative of massive sulfide and ultramafic lithology types from the Kabanga North and Tembo zones (refer to Lifezone’s December 7, 2023 news release), has demonstrated high recoveries of nickel, copper and cobalt to concentrate.
The fully optimized locked-cycle test on an Early Years Blend Composite (“EYBC”; a composite sample that is expected to be a representative average of the first years of production from Kabanga) with a feed grade of 2.03% nickel achieved a nickel recovery of 88.2% to a concentrate grading 18.8% nickel (see Figure 1 below). The associated copper and cobalt recoveries into the concentrate were 98.2% and 91.0% at feed grades of 0.30% and 0.17%, respectively. These recoveries are notably higher than the assumed 87.2% nickel, 85.1% copper and 88.1% cobalt flotation recoveries used to calculate the December 2023 Mineral Resource Update.
This test has confirmed the historical pilot-plant results and is also in good agreement with the recovery potential as indicated from mineralogy. Lifezone Metals considers these recoveries to be excellent, the high concentrate grades present an exceptional refinery feed with low levels of deleterious elements. Further variability test work on freshly drilled core intervals was initiated in January 2024 and is currently underway to test variation in lithology.
Historical test work included bench scale, batch open-circuit and locked-cycle flotation test work and two continuous pilot-plant test campaigns. Additional test work in support of the concentrator design for the Kabanga Definitive Feasibility Study has been completed at the Bureau Veritas Laboratory in Perth, under the management of technical teams from Lifezone Metals and DRA Global – the principal consulting engineer responsible for the Kabanga Definitive Feasibility Study.
Over 120 bench-scale, batch open-circuit flotation tests, 116 bench-scale, bulk open-circuit flotation tests and one fully optimized locked-cycle test have been undertaken to date in the current phase of work.
Kahama Hydromet Refinery Test Work Shows that High Recoveries to Finished Metals are Achievable within Short Timeframes
Test work in support of the Kahama Hydromet Refinery design, using Lifezone’s Hydromet Technology, for the Kabanga DFS is continuing at Lifezone’s Laboratory in Perth, Australia, under the management of technical teams from Lifezone Metals with support from DRA Global.
Definitive Feasibility Study refinery flowsheet test work undertaken to date includes over 164 bench-scale, batch open-circuit tests and 73 bench-scale locked-cycle tests, incorporating pressure oxidation, solid-liquid separation, neutralization, upgrading and purification processing units. The work has been conducted on a range of concentrate samples generated from the flotation program, representative of massive sulfide and ultramafic lithology types from the North and Tembo zones. The objective is to characterize the unit process responses, support flowsheet design parameters and generate bulk samples for materials handling, paste fill and residue characterization test work.
Concentrate produced from grade-optimized bulk flotation test work was used for hydrometallurgical testing in support of process design, comprising North Deep massive sulfide with mining dilution and grading approximately 19% nickel, 4% copper and 2% cobalt. Concentrate pressure leach extractions through an average of 12 tests (4 open circuit and 8 locked cycle) were 98.5% for nickel, 97.2% for copper and 98.9% for cobalt. This data set has confirmed the preliminary findings previously reported and is also in good agreement with the recovery potential as indicated from mineralogy. Pressure oxidation leach rates are confirmed to be rapid (see Figure 3 below).
Locked cycle pressure oxidation – neutralization test work to track and demonstrate metal and impurity deportment is ongoing, along with further optimization of solvent extraction parameters.
Process design, procurement and fabrication activities are currently underway for a semi-continuous pilot-plant testing concentrate derived from Early Years Blend Composite for confirmation of process design criteria for the Kahama refinery treating the Kabanga nickel sulfide concentrate.
The Kahama Hydromet Refinery Receives its Environmental Impact Assessment Certificate from the Government of Tanzania
Lifezone has received the Environmental Impact Assessment certificate of approval for the establishment and operation of the Kahama Hydromet Refinery. This important milestone reflects the hard work and dedication of Lifezone’s environmental team.
Safety remains the Top Priority at Kabanga
Lifezone operates with safety as an ongoing, front of mind initiative at every level, and has recorded more than 1.7 million hours worked without a lost time injury at the Kabanga Nickel Project.
In addition, there have been zero environmental incidents year-to-date.
Qualified Persons
Scientific and technical information in this news release has been reviewed and approved by Dr. Mike Adams, DSc (Eng), PhD (Metallurgical Chemistry), who is a Fellow of The Australasian Institute of Mining and Metallurgy (AusIMM), Southern African Institute of Mining and Metallurgy, and Royal Society of Chemistry, a Qualified Person in accordance with S-K 1300. Dr. Adams is employed by Lifezone Metals as Chief Technology Officer.
If you would like to sign up for Lifezone Metals news alerts, please register here.
About Lifezone Metals
At Lifezone Metals (NYSE: LZM), our mission is to provide cleaner and more responsible metals production and recycling. Using a scalable platform underpinned by our Hydromet Technology, we offer lower energy, lower emission and lower cost metals production compared to traditional smelting.
Our Kabanga Nickel Project in Tanzania is believed to be one of the world's largest and highest-grade undeveloped nickel sulfide deposits. By pairing with our Hydromet Technology, we are working to unlock a new source of LME-grade nickel, copper and cobalt for the global battery metals markets, and empower Tanzania to achieve full in-country value creation and become the next premier source of Class 1 nickel. A Definitive Feasibility Study for the project is due for completion by Q3 2024.
Through our US-based, platinum, palladium and rhodium recycling joint venture, we are working to demonstrate that our Hydromet Technology can process and recover platinum group metals from responsibly sourced spent automotive catalytic converters in a cleaner and more efficient way than conventional smelting and refining methods.
Cautionary Statement
The Definitive Feasibility Study is a work-in-progress and mine planning continues, including the application of modifying factors to establish the economic viability of Mineral Reserves. Information provided in this news release is current at the date of this release and may be subject to change as the Definitive Feasibility Study progresses.
Forward-Looking Statements
Certain statements made herein are not historical facts but may be considered “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended and the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995 regarding, amongst other things, the plans, strategies, and prospects, both business and financial, of Lifezone Metals Limited and its subsidiaries and/or affiliates.
Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters; provided that the absence of these does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding future events, the estimated or anticipated future results of Lifezone Metals, future opportunities for Lifezone Metals, including the efficacy of Lifezone Metals’ hydrometallurgical technology (Hydromet Technology) and the development of, and processing of mineral resources at, the Kabanga Project, and other statements that are not historical facts.
These statements are based on the current expectations of Lifezone Metals’ management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Lifezone Metals and its subsidiaries. These statements are subject to a number of risks and uncertainties regarding Lifezone Metals’ business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions, including but not limited to the economic and operational disruptions; global inflation and cost increases for materials and services; reliability of sampling; success of any pilot work; capital and operating costs varying significantly from estimates; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; changes in government regulations, legislation and rates of taxation; inflation; changes in exchange rates and the availability of foreign exchange; fluctuations in commodity prices; delays in the development of projects and other factors; the outcome of any legal proceedings that may be instituted against the Lifezone Metals; our ability to obtain additional capital, including use of the debt market, future capital requirements and sources and uses of cash; the risks related to the rollout of Lifezone Metals’ business, the efficacy of the Hydromet Technology, and the timing of expected business milestones; the acquisition of, maintenance of and protection of intellectual property; Lifezone’s ability to achieve projections and anticipate uncertainties relating to our business, operations and financial performance, including: expectations with respect to financial and business performance, financial projections and business metrics and any underlying assumptions; expectations regarding product and technology development and pipeline; the effects of competition on Lifezone Metals’ business; the ability of Lifezone Metals to execute its growth strategy, manage growth profitably and retain its key employees; the ability of Lifezone Metals to reach and maintain profitability; enhancing future operating and financial results; complying with laws and regulations applicable to Lifezone Metals’ business; Lifezone Metals’ ability to continue to comply with applicable listing standards of the NYSE; the ability of Lifezone Metals to maintain the listing of its securities on a U.S. national securities exchange; our ability to comply with applicable laws and regulations; stay abreast of modified or new laws and regulations applying to our business, including privacy regulation; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (SEC).
The foregoing list of risk factors is not exhaustive. There may be additional risks that Lifezone Metals presently does not know or that Lifezone Metals currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Lifezone Metals’ expectations, plans or forecasts of future events and views as of the date of this communication. Lifezone Metals anticipates that subsequent events and developments will cause Lifezone Metals’ assessments to change. However, while Lifezone Metals may elect to update these forward-looking statements in the future, Lifezone Metals specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as representing Lifezone Metals’ assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Nothing herein should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results in such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which are based upon information available to us as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. In all cases where historical performance is presented, please note that past performance is not a credible indicator of future results.
Except as otherwise required by applicable law, we disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data, or methods, future events, or other changes after the date of this communication, except as required by applicable law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226757968/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
